Dr. Alex Adjei, from Roswell Park Cancer Institute, on the Need for Targeted Therapy Education
Alex A. Adjei, MD, PhD, Professor and Chair, Department of Medicine, Katherine Anne Gioia Chair in Cancer Medicine, Senior Vice President, Clinical Research, Roswell Park Cancer Institute, discusses the 10th International Congress on Targeted Therapies in Cancer (ICTTC), which is designed to provide information on targeted anticancer therapies.
For many practices and oncologists, it can be a challenge to keep up to date on the development of new therapies and drugs, as well as how to manage side effects, how to best utilize new drugs, and what populations the drugs should be used in. A number of new advances will be discussed at ICTTC, including c-Met inhibitors, MEK inhibitors, and immunotherapy.
Adjei says that with so many new advances, the ICTTC is more relevant than ever. At the meeting, recently approved drugs such as vemurafenib and crizotinib will be discussed in addition to newer drugs that have not yet entered the clinical setting. There will also be a section focused on immunotherapy that will deal with the tumor microenvironment.
The meeting is held August 17-18, 2012, at the Mayflower Renaissance Hotel, in Washington, DC.